What is Oblenio Bio?
Oblenio Bio is a specialized biotechnology enterprise dedicated to the development of next-generation immunotherapies. The company’s core innovation lies in its tri-specific T-cell engager therapies, which are engineered to selectively deplete pathogenic immune cells. By targeting the fundamental mechanisms of autoimmune disorders, the company aims to achieve a long-term immune reset, offering patients the prospect of durable, drug-free remission. This focus on precision medicine places Oblenio Bio at the forefront of the immunology sector, where it competes by offering more targeted and effective alternatives to conventional immunosuppressive treatments.
How much funding has Oblenio Bio raised?
Oblenio Bio has raised a total of $62M across 1 funding round:
Series B
$62M
Series B (2026): $62M with participation from GV, Aditum Bio, Pfizer, and Deep Track Capital
Key Investors in Oblenio Bio
GV
GV is a prominent venture capital firm that invests across multiple stages and sectors, with a strong emphasis on life sciences and frontier technology innovations.
Aditum Bio
Aditum Bio is a specialized biotech venture capital firm focused on rapidly translating scientific discoveries into innovative medicines to bridge the gap between research and patient care.
Pfizer
Pfizer Inc. is a global biopharmaceutical leader dedicated to discovering and developing breakthrough therapies and vaccines to address significant health challenges.
What's next for Oblenio Bio?
With the successful closure of this major strategic investment, Oblenio Bio is poised to transition its lead candidates into more advanced clinical stages. The company’s strategic roadmap involves scaling its research and development infrastructure to support the rigorous testing required for its tri-specific T-cell engager platform. Furthermore, the involvement of major industry partners suggests a potential for future collaborative development or licensing agreements that could expedite the path to commercialization. As the firm continues to refine its therapeutic modalities, the focus will remain on validating the safety and efficacy of its immune-reset technology in human trials, ultimately aiming to redefine the standard of care for patients suffering from chronic autoimmune diseases.
See full Oblenio Bio company page
